Soho Flordis International (SFI), an international provider of clinically proven natural medicines, announced the acquisition of ProThera, a leading nutraceutical company based in Reno, Nev. The acquisition marks an important milestone in establishing SFI as the leading global provider of clinically proven natural medicine.
With over 50 years of formulation experience and a comprehensive product line of probiotics and dietary supplements distributed exclusively by healthcare providers, ProThera gives SFI entry into both the growing field of probiotics and the U.S. market, further delivering on its mission to give health care providers and patients access to the best natural medicine supported by clinical studies.
ProThera headquarters in Reno will serve as a regional hub for the rapid commercialization of the extensive SFI Group product portfolio and future pipeline.
In a corresponding move, SFI today announced the acquisition of Ginsana, a leader and innovator in natural medicine products based in Bioggio, Switzerland. Owned by Pharmaton, a Boehringer Ingelheim Group company, Ginsana brings superior expertise, state-of-the-art facilities and a complementary line of six natural medicine brands with significant growth potential to the SFI portfolio. Ginsana will continue to market its products under the Ginsana brand name and manufacture world class natural medicines. The trademark rights of Pharmaton remain at Pharmaton.
"The parallel acquisition of ProThera and Ginsana not only gives us entry into the attractive field of probiotics, it has extended our network and pipeline of natural medicine brands with a great legacy," said SFI CEO Nigel Pollard. "Building on our success in the southern hemisphere—in Australia and South Africa—we have now established a strong foundation for expansion in the northern hemisphere and its main markets, the U.S., Europe, Middle East and Asia. Both companies reflect SFI's dedication to innovation and the advancement of natural medicines through healthcare providers."